MedTrace Logo

Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients

NCT02297763 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2014-11-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of low dose quetiapine for the prophylaxis of delirium in critically ill patients in medical intensive care unit.

Conditions

  • Delirium

Interventions

DRUG

quetiapine

patient body weight \<50kg : quetiapine 12.5mg patient body weight \>=50kg : quetiapine 25mg quetiapine 12.5mg (bwt \<50kg ) or 25mg (bwt\>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form. The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water).

DRUG

placebo

The placebo is made of 100mg of corn starch which is melted in 10cc water.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02297763 on ClinicalTrials.gov